SCYNEXIS, Inc. Proceeds from Sale and Maturity of Held-to-maturity Securities
SCYNEXIS, Inc. (SCYX) reported Proceeds from Sale and Maturity of Held-to-maturity Securities of $14.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities · last filed 2026-08-10
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2026-06-30 was $11.46M, a 1.61% increase year-over-year.
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2026-03-31 was $2.75M, a 77.89% decline year-over-year.
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2025-12-31 was $7.08M, a 21.74% increase year-over-year.
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2025-09-30 was $12.42M, a 35.35% decline year-over-year.
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2025 was $43.21M, a 1.51% increase from fiscal 2024.
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2024 was $42.57M, a 15.88% decline from fiscal 2023.
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2023 was $50.60M.
- SCYNEXIS, Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale and Maturity of Held-to-maturity Securities 3 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 6 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 9 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $14.21M 10-Q · filed 2026-08-10 | $21.28M derived: sum of 3 quarters · filed 2026-08-10 | $33.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $2.75M 10-Q · filed 2026-05-11 | $9.83M derived: sum of 2 quarters · filed 2026-05-11 | $22.25M derived: sum of 3 quarters · filed 2026-05-11 | $33.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $19.50M derived: sum of 2 quarters · filed 2026-03-04 | $30.77M derived: sum of 3 quarters · filed 2026-08-10 | $43.21M 10-K · filed 2026-03-04 |
| 2025-09-30 | $12.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $23.69M derived: sum of 2 quarters · filed 2026-08-10 | $36.13M 10-Q · filed 2025-11-05 | $41.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $11.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $23.71M 10-Q · filed 2026-08-10 | $29.53M derived: sum of 3 quarters · filed 2026-08-10 | $48.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $12.44M 10-Q · filed 2026-05-11 | $18.25M derived: sum of 2 quarters · filed 2026-05-11 | $37.46M derived: sum of 3 quarters · filed 2026-05-11 | $47.04M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $25.02M derived: sum of 2 quarters · filed 2026-03-04 | $34.60M derived: sum of 3 quarters · filed 2026-03-04 | $42.57M 10-K · filed 2026-03-04 |
| 2024-09-30 | $19.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $28.79M derived: sum of 2 quarters · filed 2025-11-05 | $36.75M 10-Q · filed 2025-11-05 | $46.80M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $9.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $17.55M 10-Q · filed 2025-08-13 | $27.60M derived: sum of 3 quarters · filed 2025-08-13 | $47.59M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $7.96M 10-Q · filed 2025-05-15 | $18.02M derived: sum of 2 quarters · filed 2025-05-15 | $38.01M derived: sum of 3 quarters · filed 2025-05-15 | $58.57M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $10.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $30.05M derived: sum of 2 quarters · filed 2025-03-12 | $50.60M derived: sum of 3 quarters · filed 2025-03-12 | $50.60M 10-K · filed 2025-03-12 |
| 2023-09-30 | $19.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $40.55M derived: sum of 2 quarters · filed 2024-11-06 | $40.55M 10-Q · filed 2024-11-06 | $40.55M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $20.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $20.56M 10-Q · filed 2024-08-08 | $20.56M derived: sum of 3 quarters · filed 2024-08-08 | $20.56M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2024-05-08 | $0.00 derived: sum of 3 quarters · filed 2024-05-08 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |